TROP2-directed antibody–drug conjugate (SKB264/MK-2870) delivering a topoisomerase I inhibitor to TROP2-positive tumor cells.
Humanized anti-TROP2 IgG1 ADC that binds TROP2 on tumor cells; following internalization and pH-sensitive/enzymatic cleavage of the linker, it releases the topoisomerase I inhibitor tirumotecan, inhibiting DNA replication and causing cell-cycle arrest and apoptosis, with a bystander effect on adjacent tumor cells.
YES
DIRECT
The ADC binds TROP2 on target cells, is internalized, and releases the topoisomerase I inhibitor tirumotecan, inhibiting DNA replication and causing cell-cycle arrest and apoptosis (with possible bystander killing).
TROP2-directed antibody–drug conjugate (SKB264/MK-2870) delivering a topoisomerase I inhibitor to TROP2-positive tumor cells.
Humanized anti-TROP2 IgG1 ADC that binds TROP2 on tumor cells; following internalization and pH-sensitive/enzymatic cleavage of the linker, it releases the topoisomerase I inhibitor tirumotecan, inhibiting DNA replication and causing cell-cycle arrest and apoptosis, with a bystander effect on adjacent tumor cells.
NO
INDIRECT
The ADC targets TROP2 on tumor cells for delivery; after internalization, it releases tirumotecan, which inhibits DNA topoisomerase I to block DNA replication and induce apoptosis. Topoisomerase I is the payload’s enzymatic target, not the targeting antigen.
Bispecific T-cell–engager antibody (BCMA × CD3) that redirects T cells to kill BCMA-expressing myeloma cells.
Bispecific antibody that binds BCMA on myeloma cells and CD3 on T cells, forming an immune synapse that redirects and activates cytotoxic T cells to kill BCMA-expressing plasma cells via perforin/granzyme-mediated lysis, independent of MHC.
YES
DIRECT
BCMA+ cells are bridged to CD3+ T cells by the bispecific, forming an immune synapse that triggers T‑cell–mediated killing via perforin/granzyme release (MHC-independent).
Bispecific T-cell–engager antibody (BCMA × CD3) that redirects T cells to kill BCMA-expressing myeloma cells.
Bispecific antibody that binds BCMA on myeloma cells and CD3 on T cells, forming an immune synapse that redirects and activates cytotoxic T cells to kill BCMA-expressing plasma cells via perforin/granzyme-mediated lysis, independent of MHC.
NO
INDIRECT
The drug binds CD3 on T cells to activate and redirect them to kill BCMA-expressing tumor cells via perforin/granzyme; CD3+ cells are not killed.
Anti-CD38 IgG1 monoclonal antibody that depletes CD38+ cells via ADCC, CDC, ADCP, and apoptosis.
Human IgG1κ monoclonal antibody targeting CD38 on myeloma and other CD38+ cells; induces tumor cell killing via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and direct apoptosis, and depletes CD38+ immunosuppressive cells (e.g., Tregs, B cells, MDSCs) to modulate the tumor microenvironment.
YES
DIRECT
Binds CD38 on target cells and triggers Fc-mediated ADCC, CDC, and ADCP, and can induce direct apoptosis of CD38+ cells.